To examine the impact of additional confounder adjustment for the potential association between second line T2DM therapy and thyroid cancer: a nested case-control study (GLP1i and thyroid cancer)

Study type

• Study type:
  Non-interventional study
• Scope of the study:
  Assessment of risk minimisation measure implementation or effectiveness

  Other
• If ‘other’, further details on the scope of the study:
  evaluation of counfounders impact

Non-interventional study

• Non-interventional study design:
  Case-control

Study drug and medical condition

• Anatomical Therapeutic Chemical (ATC) code:
  (A10BJ) Glucagon-like peptide-1 (GLP-1) analogues

  Glucagon-like peptide-1 (GLP-1) analogues
• Medical condition to be studied:
  Thyroid cancer

Population studied

• Age groups:
  • Adults (18 to < 46 years)
  • Adults (46 to < 65 years)
  • Adults (65 to < 75 years)
  • Adults (75 to < 85 years)
  • Adults (85 years and over)
• Estimated number of subjects:
  64000

Study design details

• Main study objective:
  To calculate crude and adjusted effect estimates for GLP1-agonists and the association with thyroid cancer based upon the design for confounding adjustment in the study by Bezin et al. study. To determine the impact of additional adjustment for smoking status, BMI, and history of alcohol use/abuse on the effect estimates for GLP1-agonists (+/- other seco
• Outcomes:
  Thyroid cancer
• Data analysis plan:
  A cohort of diabetic patients will be created. From this, controls will be sampled through risk set sampling, matched for age, gender, cohort follow-up, and diabetes duration. The matching approach may be refined depending on the feasibility of identifying controls. Conditional logistic regression will be used to examine the association between each exposure and outcome. Odds ratios in this context can be considered akin to rate ratios.